All articles tagged with #chronic liver disease
A study from UK universities found that drinking three to four cups of coffee daily can reduce the risk of fatty liver disease by 20% and death from chronic liver disease by 49%, with benefits observed for both caffeinated and decaffeinated coffee, especially ground coffee.
Pliant Therapeutics' drug bexotegrast shows consistent safety across dose ranges in a Phase IIa trial for primary sclerosing cholangitis (PSC), although the highest dose did not demonstrate improved activity over lower doses based on new biomarker data. Analysts remain optimistic about the drug's overall development, as it inhibits two integrins to block the activation of TGF-beta, a central mediator of fibrosis in PSC patients.
Pliant Therapeutics has reported positive early-stage results from an exploratory study, indicating that patients with chronic liver disease who received its drug, bexotegrast, showed improved liver function compared to those who received a placebo. The study showed reduced levels of liver scarring biomarkers in patients who received the drug.
A study conducted by researchers from Brigham and Women's Hospital found that postmenopausal women who consume daily sugar-sweetened beverages have a significantly higher risk of liver cancer and chronic liver disease mortality compared to those who consume fewer drinks. The study included nearly 100,000 postmenopausal women and observed a strong association between the consumption of sugary drinks and liver-related outcomes. However, the study was observational, and more research is needed to validate the risk association and understand the underlying mechanisms. These findings highlight the potential need for public health strategies to reduce the consumption of sugar-sweetened beverages and mitigate the risk of liver disease.
Women who consume sugar-sweetened beverages daily are at a higher risk of developing liver cancer and chronic liver disease, according to a study led by Brigham and Women's Hospital. The study, which included nearly 100,000 postmenopausal women, found that those who consumed one or more sugar-sweetened beverages per day had an 85% higher risk of liver cancer and a 68% higher risk of chronic liver disease mortality compared to those who consumed fewer than three such beverages per month. However, the study was observational, and more research is needed to establish a causal relationship and understand the underlying mechanisms. Approximately 65% of adults in the US consume sugar-sweetened beverages daily.
A study published in JAMA found that postmenopausal women who consume just one sugar-sweetened beverage per day have a significantly higher risk of developing liver cancer and dying from chronic liver disease. The research, which observed nearly 100,000 American women over 20 years, revealed that those who drank at least one sweetened soft drink or fruit drink daily were 1.75 times more likely to be diagnosed with liver cancer and 2.5 times more likely to die from chronic liver disease compared to those who consumed three or fewer of these beverages per month. The study also highlighted the detrimental health consequences of fructose intake and the risks associated with sugary drinks, including obesity, diabetes, and liver diseases.
A new study published in JAMA found that older women who consume sugar-sweetened beverages daily face a higher risk of liver cancer and death from chronic liver disease. The study, which tracked the beverage choices of nearly 100,000 women over two decades, revealed that those who drank at least one sugar-sweetened beverage a day were 1.75 times more likely to be diagnosed with liver cancer and nearly 2.5 times more likely to die from chronic liver disease. However, women who consumed artificially sweetened drinks did not have a significantly higher risk. While the study does not establish a cause-and-effect relationship, experts suggest that reducing the consumption of sugar-sweetened beverages could be a public health strategy to reduce the burden of liver disease.
Clonal hematopoiesis, a genetic condition that increases the risk of blood cancer, may also increase the risk of chronic liver disease by promoting inflammation in the liver. Researchers found that mice with clonal hematopoiesis developed more severe liver fibrosis and inflammation when fed a high-fat diet. The study suggests that clonal hematopoiesis may be a previously unrecognized risk factor for chronic liver disease.